Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91®) in cynomolgus monkeys following intravenous infusion

Antisense and Nucleic Acid Drug Development

Volumn 8, Issue 1, 1998, Pages 43-52

  Michael Grindel, J ^a   Musick, Timothy J ^b   Jiang, Zhiwei ^a   Roskey, Allysen ^a   Agrawal, Sudhir ^a  

^a HYBRIDON INC   (United States)

^b Late Stage Developmental Services Covance Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PHOSPHORUS 32; SULFUR 35;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; DRUG ELIMINATION; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; LIVER LEVEL; LYMPH NODE; MONKEY; NONHUMAN; NUCLEIC ACID METABOLISM; PHARMACOKINETICS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SPLEEN; URINARY EXCRETION;

EID: 0031910668     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.1998.8.43     Document Type: Article

References (4)

1. AGRAWAL, S., ed. (1996a). Antisense Therapeutics. (Humana Press, Inc., Totowa, NJ).
2. AGRAWAL, S. (1996b). Antisense oligonucleotides: Towards clinical trials. Trends Biotechnol. 14, 376-387.
3. AGRAWAL, S., JIANG, Z., ZHAO, Q., SHAW, D., CAI, Q., ROSKEY, A., CHANNAVAJJALA, L., SAXINGER, C., and ZHANG, R. (1997a). Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies. Proc. Natl. Acad. Sci. USA 94, 2620-2625.
4. ZHANG, R., YAN, J., SHAHINIAN, H., AMIN, G., LU, Z., LIU, T., SAAG, M.S., JIANG, Z., TEMSAMANI, J., MARTIN, R.R., et al. (1995d). Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin. Pharmacol. Ther. 58, 44-53.